Investorideas.com newswire, breaking biotechnology and pharma news

Friday, March 10, 2017

This Week’s Tech, Biotech, Energy, LOHAS, Renewable, Homebuilding & Mining Stocks added to InvestorIdeas Directories

This Week’s Tech, Biotech, Energy, LOHAS, Renewable, Homebuilding & Mining Stocks added to InvestorIdeas Directories

New Tech Stocks: $SNAP, $BNS, $UAV.CA, $BSFT, $MRM.CA, $DVR.CA, $PEGA $ADGO.L



Point Roberts, WA, Delta BC – March 10, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its investor membership, including global stock directories in technology, biotech, energy, LOHAS, renewable, homebuilding and mining.

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

New tech companies include software stocks, bitcoin/blockchain companies, Artificial Intelligence (AI)/robotics companies and those involved in social media such as Snap Inc. (NYSE: SNAP) and cloud computing such as BroadSoft, Inc. (Nasdaq:BSFT).

New drone stocks have been added both the tech and defense stock lists and include Deveron UAS Corp. (CSE:DVR) and Alta Vista Ventures Ltd. (CSE:UAV). 

Biotech stock additions include Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX) which has been named one of Science Magazine’s ‘Top Employers in the life sciences’ for seven years in a row. 

The newest energy company, Jones Energy, Inc. (NYSE:JONE) is involved in both oil and natural gas exploration with the United States and the latest LOHAS stock is a nutraceutical company focussed on the benefits of blueberries.

The SWISS-traded energy storage company Leclanché SA (SIX: LECN) has been added to our renewable energy stocks directory and the latest homebuilder stock is The New Home Company (NYSE: NWHM), a new generation homebuilder focused on select growth markets in California and Arizona.

The latest mining stock is a TSX-listed potash mining company operating in New Mexico, IC Potash Corp.  This stock also crosses over into the agriculture sector as it is currently examining ways to become a low-cost fertilizer producer.


New Tech Companies Added:
Snap Inc. (NYSE: SNAP) operates as a camera company. It offers Snapchat, a camera application that helps people to communicate through short videos and images. The company also provides a suite of content tools for partners to build, edit, and publish snaps and attachments based on editorial content; and Spectacles, which are sunglasses that capture video from a human perspective. The company was formerly known as Snapchat, Inc. and changed its name to Snap Inc. in September 2016.

Scotiabank (NYSE: BNS; TSX:BNS.TO) is Canada's international bank and a leading financial services provider in North America, Latin America, the Caribbean and Central America, and Asia-Pacific. We are dedicated to helping our 23 million customers become better off through a broad range of advice, products and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. With a team of more than 88,000 employees and assets of $896 billion.  Blockchain trial with AlphaPoint

Alta Vista Ventures Ltd. (CSE:UAV)  is the frontrunner in the Unmanned Aerial Vehicle (UAV) industry. In Spanish, Alta Vista translates to "High View". Alta Vista is entering the Unmanned Aerial Vehicle (UAV) sector by consolidating a diverse group of established, profitable UAV companies to create a leading service provider.

BroadSoft, Inc. (NASDAQGS:BSFT) is the technology innovator in cloud communications, collaboration, and contact center solutions for businesses and service providers across 80 countries. We are the market share leader for cloud unified communications with an open, mobile and secure platform trusted by 25 of the world’s top 30 service providers by revenue. Our BroadSoft Business application suite empowers users and teams to share ideas and work simply to achieve breakthrough performance.

Micromem Technologies Inc. (CSE: MRM; OTCQX: MMTIF) leads the world with viable sensor applications; and, designs, develops and provide sensors specific to industry needs. MASTInc is a wholly owned U.S.-based subsidiary of Micromem Technologies Inc., a publicly traded (OTCQX: MMTIF) (CSE: MRM) company. MASTInc analyzes specific industry sectors to create intelligent game-changing applications that address unmet market needs. By leveraging its expertise and experience with sophisticated magnetic sensor applications, MASTInc successfully powers the development and implementation of innovative solutions for oil & gas, utilities, automotive, healthcare, government, information technology, manufacturing, and other industries.

Deveron UAS Corp. (CSE:DVR) is an enterprise drone data services company focused on agriculture, offering the opportunity to increase yields and reduce costs using sophisticated Unmanned Aerial Systems ("UAS" or "drones"), sensors, software and analytics. Deveron's drone data service network allows enterprise level customers to obtain on-demand, actionable data without exposure to technology and capital risks. The Company is focused on building a standardized constellation of drones and sensors to provide data in North America.

Adgorithms (LSE:ADGO.L) are the creators of Albert, the world’s first and only completely self-driven artificial intelligence marketing platform. Albert is the first-ever artificial intelligence marketing platform, driving fully autonomous digital marketing campaigns for some of the world’s leading brands. Created by Adgorithms in 2010, Albert’s mission is to liberate businesses from the complexities of digital marketing—not just by replicating their existing efforts, but by executing them at a pace and scale not previously possible. He serves as a highly intelligent and sophisticated member of brands’ marketing teams, wading through mass amounts of data, converting this data into insights, and autonomously acting on these insights, across channels, devices and formats, in real time. This eliminates the manual and time-consuming tasks that currently limit the effectiveness and results of modern digital advertising and marketing. Brands such as Harley Davidson, EVISU, Planet Blue, and Made.com credit Albert with significantly increased sales, an accelerated path to revenue, the ability to make more informed investment decisions, and reduced operational costs.

Pegasystems Inc. (NasdaqGS: PEGA) develops strategic applications for marketing, sales, service, and operations. Pega's applications streamline critical business operations, connect enterprises to their customers seamlessly in real-time across channels, and adapt to meet rapidly changing requirements. Pega's Global 3000 customers include many of the world's most sophisticated and successful enterprises. Pega's applications, available in the cloud or on-premises, are built on its unified Pega® Platform, which uses visual tools to easily extend and change applications to meet clients' strategic business needs. Pega's clients report that Pega gives them the fastest time to value, extremely rapid deployment, efficient re-use, and global scale. Pega has announced new artificial intelligence (AI) and robotic automation capabilities in its customer relationship management (CRM) offerings that enable businesses to optimize their sales and customer service effectiveness with desktop analytics and machine learning.

New Biotech Companies Added:
Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX) is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For seven years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.

New Energy Companies Added:
Jones Energy, Inc. (NYSE:JONE) is an independent oil and natural gas company engaged in the development and acquisition of oil and natural gas properties in the Anadarko and Arkoma basins of Texas and Oklahoma.

New LOHAS Companies Added:
NeutriSci International Inc. (TSX:NU.V; OTC:NRXCF) specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci is currently focused on building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company's natural energy and focus supplement that has at its core, the beneficial effects of blueberries. Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products.

New Renewable Companies Added:
Leclanché SA (SIX: LECN) is one of the world's leading fully vertically integrated energy storage solution providers. It delivers a wide range of energy storage solutions for homes, small offices, large industries, electricity grids, as well as hybridization for mass transport systems such as bus fleets and ferries. Established in 1909, Leclanché has been a trusted provider of battery energy storage solutions for over 100 years. Founded in the tradition of Georges Leclanché, the inventor of the dry cell battery, Leclanché today has a rich portfolio of Battery Energy Storage Systems (BESS) that include bespoke battery systems from industry leading lithium-ion solutions.

New Homebuilder Companies Added:
New Home Company, The (NYSE: NWHM) is a new generation homebuilder focused on the design, construction and sale of innovative and consumer-driven homes in major metropolitan areas within select growth markets in California and Arizona, including coastal Southern California, the San Francisco Bay area, metro Sacramento and Phoenix.

New Mining Companies Added:
IC Potash Corp. (TSX: ICP.TO; OTCQX: ICPTF) has previously demonstrated a method to make Sulfate of Potash (“SOP”) from its 100%-owned Ochoa polyhalite deposit in Southeast New Mexico and is currently examining ways to become a low-cost fertilizer producer. The current review of IC Potash’s existing feasibility study is being extended to determine a viable positive economic path to the production of direct application polyhalite. The Ochoa project has access to excellent local labor resources, low-cost electricity and natural gas, water, rail lines, and the Port of Galveston, Texas. IC Potash’s land holdings consist of nearly 90,000 acres of federal subsurface potassium prospecting permits and State of New Mexico potassium mining leases.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.  

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411










Friday, March 3, 2017

This Week’s Biotech, Energy and Mining Stocks added to InvestorIdeas Directories

This Week’s Biotech, Energy and Mining Stocks added to InvestorIdeas Directories



Point Roberts, WA, Delta BC – March 3, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its investor membership, including global stock directories in biotech, energy and mining

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

The latest biotech companies include Kalytera Therapeutics, Inc. (TSX: KALY.V) which is working with advancing CBD therapies and thus crosses into our cannabis stocks list.

The newest energy company is Molori Energy Inc. (TSX: MOL.V; OTCQB: MOLOF), an oil and gas production company with current operations in the Texas Panhandle.

Both new mining companies are Canadian listed and active in lithium as well as other metals and are also now listed on our renewable energy stock list in the lithium section. Power Americas Minerals Corp. (TSX:PAM.V) (formerly Victory Ventures) has operations in South America and is included in our North American stocks doing business in Latin America – Chile, Peru, Mexico and Colombia list.


New Biotech Companies Added:
Kalytera Therapeutics, Inc. (TSX: KALY.V) is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs. Kalytera is focused first on developing a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability and short half-life. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.

New Energy Companies Added:
Molori Energy Inc. (TSX: MOL.V; (OTCQB: MOLOF)  is an oil and gas production company with current operations in the Texas Panhandle. Founded in 2011, the experienced management team is aggressively acquiring select properties which provide immediate cash flow and development opportunities, now and in the years ahead. Molori is seizing the opportunity, in the current oil & gas environment, to assemble oil and gas production in nearby and politically safe jurisdictions. Molori is pursuing a business plan, whereby the Company either purchases producing oil and gas assets at highly attractive rates, or in some cases simply takes on existing assets by way of purchasing or assuming default notes from small regional lenders and institutions.

New Mining Companies Added:
One World Minerals Inc. (CSE:OWM) is a successful exploration and development Company with geologists having experience over the last 30 years in gold, silver, base metals and lithium.

Power Americas Minerals Corp. (TSX:PAM.V) (formerly Victory Ventures) acquisition strategy focuses on acquiring affordable, cost effective and highly regarded mineral properties in areas with proven geological potential. These areas include historical and currently producing mines with existing infrastructure. This strategy includes acquiring 100% interests in mineral properties, with no payment terms or work program commitments that would threaten a junior mining company's financial stability. The Company believes it can create maximum shareholder value efficiently and cost effectively implementing this acquisition strategy. The Company believes that the demand profile for Cobalt, Lithium, Copper, and other essential power related materials will be fundamentally led by the growing adaptation of electric vehicles, renewable energy and increased production of super alloys. With a focus on identifying and developing ethically sourced materials within the Americas, the Company intends to address the growing demand for energy metals that are being driven by innovation and the introduction of new technologies. Power Americas Minerals Corp. is a Canadian-based junior mining exploration company focused on the procurement, exploration and development of cobalt, lithium, copper and other energy metals in North and South America.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.  

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411









Thursday, March 2, 2017

Biodefense Stocks News: Aethlon Medical (NASDAQ: $AEMD) CEO Note: Bill Gates on the Threat of Bioterrorism

Biodefense Stocks News: Aethlon Medical (NASDAQ: $AEMD) CEO Note:  Bill Gates on the Threat of Bioterrorism




SAN DIEGO, CA (Investorideas Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), recently released the following note authored by its Chairman and CEO, Jim Joyce.

In a chilling address at the Munich Security Conference last Saturday, Bill Gates warned world leaders that a genetically engineered virus could kill more people than nuclear weapons. Mr. Gates expressed his concern, which is also supported by U.S. and U.K. intelligence agencies, that scientific terrorists have access to the necessary tools to design biological viruses to be weapons that could kill tens of millions of people. He also concluded that in the face of such knowledge, governments around the world remain complacent and are neither prepared nor equipped to respond to these threats.

If you are a shareholder of Aethlon Medical, you may recognize the concerns of Mr. Gates to be eerily similar to our own. As a recent example, I encourage you to review the bioterror related article that we published last year on the 21st of December.


For those dedicated to the advancement of bioterror treatment solutions, Mr. Gates is a welcome and respected voice with the visibility, influence and knowledge to recognize that therapeutic innovation will be required to counter deadly viruses created by man.

If bioterrorists were to release such a virus, I am sincerely unaware of a clinical-stage candidate beyond our Hemopurifier® that could be deployed as a post-exposure treatment countermeasure.

The void in bioterrorism treatment countermeasures is driven by a historic emphasis to align a disease-specific drug or vaccine which only targets one specific pathogen threat. Such strategies have had limited success against the breadth of threats that are known to be infectious to man and cannot be considered as a strategy to treat unknown viruses created by man.

In reality, only a fraction of the 300+ viruses known to be infectious to man are addressed with an FDA-cleared drug or vaccine.  Since 2001, our government has spent an estimated $80 billion on biodefense initiatives, yet just one of 13 viruses classified as "Category A" are addressed with an approved therapy.  "Category A" pathogens are those biological threats that pose the highest risk to national security and public health.  In addition, these types of viral pathogens maintain the potential to be genetically engineered to be used as weapons that are even more deadly and resistant than those viruses that are naturally occurring.

Our Hemopurifier® is a first-in-class medical technology currently being advanced in FDA approved studies.  In previous studies, our technology has demonstrated the ability to capture a wide range of bioterror related, pandemic, chronic and latent infectious viral pathogens.

We believe the Hemopurifier® can fulfill the broad-spectrum medical countermeasure objective of the U.S. Department of Health and Human Services (HHS) Public Health Emergency Medical Countermeasure Enterprise (PHEMCE).  This initiative is directed toward bioterror, pandemic threats and other pathogens that are not well addressed with traditional drug or vaccine therapies.

A little more than a decade ago, we were invited to attend an international scientific symposium hosted by the National Center for Biodefense. At the time, our Hemopurifier® was still a development-stage vision. Regardless, the keynote speaker, who formerly led the Soviet Union's biological weapons program, emphasized our approach to be the only way to counter the breadth of viruses that could emerge naturally through mother nature or be created by man as agents of bioterror.

We never forgot that statement.




About the Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical technology currently being advanced in FDA approved studies as a broad-spectrum treatment countermeasure against infectious viral pathogens.  Named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine, the Hemopurifier® has previously been administered to individuals infected with Ebola virus, Hepatitis C virus and the Human Immunodeficiency virus, which leads to HIV AIDS.

Beyond human treatment experiences, pre-clinical Hemopurifier® studies have validated the capture of Chikungunya, Dengue, Middle East Respiratory Syndrome Coronavirus, West Nile and Zika virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection.  Specific to pandemic influenza threats, Aethlon has validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus, which represents a model for the strain of influenza that killed an estimated 50 million victims in 1918 and 1919.

The Hemopurifier has also been demonstrated to capture Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1), which are latent viruses often associated with increased mortality in immune-suppressed sepsis patients.  These pathogens also contribute to organ rejection in transplant patients.  To validate treatment performance, the Hemopurifier is supported by the HP Virus Capture Assay, which quantifies the number of viruses captured within the Hemopurifier and no longer circulating in the patient.

About Aethlon Medical
Aethlon Medical (AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer.  To augment the body's natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.  Aethlon is part of the Russell Microcap® Index.  Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, including any products relating to the Zika or MERS-CoV viruses or relating to sepsis, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2016, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-489-7800 extension 3300

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: AEMD is a previous showcase company.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.



BioDefenseStocks.com - investing ideas in biodefense stocks

Like Biodefense Stocks? View our Biodefense Stocks Directory




Friday, February 24, 2017

This Week’s Biotech, Nanotech and Mining Stocks also added to Investor Directories

This Week’s Biotech, Nanotech and Mining Stocks also added to Investor Directories



Point Roberts, WA, Delta BC – February 24, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its investor membership, including global stock directories in biotech, nanotech and mining

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

The latest Biotech companies include those working with cannabinoids along with companies working in pain management, oncology, weight management, cystic fibrosis, OTC Medications, treatment for neurological diseases such as Alzheimer’s and ALS, kidney and vascular disease and new oral drug delivery systems.

Nanotech company additions coincide with a fully updated Nanotechnology stock list and include a cross-over company into the biotech sector, a company that provides nanotech tools and an investment company that has formed a joint partnership with Vietnam-based Nanotech firm.

See Nanotech stocks directory preview at http://www.investorideas.com/Nanotechnology/

New mining companies are both operating in Canada (Ontario and Quebec) and mining for copper and gold respectively.


New Biotech Companies Added:
Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA) a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. One of the products under development is APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. The company also manufactures drug products under a manufacturing services agreement for Siegfried AG

Cara Therapeutics, Inc. (NasdaqGM:CARA) is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

Cerulean Pharma Inc. (NasdaqGM:CERU) The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our first platform-generated NDC clinical candidate, CRLX101, is in clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated NDC clinical candidate, CRLX301, is in a Phase 1/2a clinical trial.

Corbus Pharmaceuticals Holdings, Inc. (NasdaqGM:CRBP) is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, JBT- 101, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation, and fibrotic processes. In November 2016, Corbus reported positive topline data results from a Phase 2 study in diffuse cutaneous systemic sclerosis, showing clear signal of clinical benefit with JBT-101. The Company recently completed a Phase 2 study of JBT-101 for the treatment of cystic fibrosis with topline data expected to be announced before the end of the first quarter of 2017. Additionally, JBT-101 is being evaluated in a Phase 2, 12-month open label extension study in systemic sclerosis, a Phase 2 study in skin-predominant dermatomyositis, with a 12-month open label extension study in dermatomyositis and another Phase 2 study in systemic lupus erythematosus planned to commence in the first quarter of 2017.

CTT Pharmaceutical Holdings Inc. (OTCQB:CTTH) principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the "Wafer"). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases including pain management. The Oral Thin Film (Wafer) formulation is protected by several Canadian and US Patents. CTT's oral fast dissolving drug delivery systems will consist of edible thin films (wafers) that dissolve without water, within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no bitter taste, no smoke inhalation as is the case with cannabis, and less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficacy of absorption. Patient compliance is improved, especially with those who have a fear of choking and/or are pediatric, geriatric or incapacitated patients who have difficulty swallowing. Most fast dissolving systems on the market today deliver anti-inflammatories, antihistamines and cough and breathing related medications. CTT believes that its Wafer technology will be one of the first to gain use in major markets such as pain management.
Innovus Pharmaceuticals, Inc. (OTC: INNV) is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

Mateon Therapeutics, Inc. (NasdaqCM: MATN) is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action. At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels. Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.

Mirna Therapeutics, Inc. (NasdaqGM: MIRN) is a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics and is the first to bring a synthetic microRNA mimic into clinical development for the treatment of cancer. Mirna's lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is being studied in a Phase 1 clinical trial which has included patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress immune checkpoint signaling molecules, including PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs an important new class of anti-cancer agents. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapies. The Company was founded in 2007 and is located in Austin, Texas.

Nivalis Therapeutics, Inc. (NasdaqGM: NVLS) is a pharmaceutical company that has historically been focused on the discovery and development of product candidates for patients with cystic fibrosis, or CF. Our GSNOR inhibitors selectively target an enzyme known as S-nitrosoglutathione reductase, which we refer to as GSNOR. GSNOR regulates levels of an endogenous protein known as S-nitrosoglutathione, or GSNO.  Depleted levels of GSNO have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. However, in light of recent disappointing results of a Phase 2 clinical trial of our lead product candidate, cavosonstat, in CF, we determined to not pursue the development of this compound in CF and to wind down our research and development activities as we shift our strategic emphasis to investigating and evaluating strategic alternatives.

Oramed Pharmaceuticals Inc. (NasdaqCM: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801).  The Company completed multiple Phase II clinical trials of ORMD-0801 under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

ProMIS Neurosciences Inc. (TSX: PMN.TO) The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS. ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

Proteon Therapeutics Inc. (NasdaqGM: PRTO) is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon is currently enrolling patients in a Phase 3 clinical trial, PATENCY-2. Proteon is also evaluating vonapanitase in Phase 1 clinical trials in patients with peripheral artery disease (PAD).

New Nanotech Companies Added:
Cerulean Pharma Inc. (NasdaqGM:CERU) The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our first platform-generated NDC clinical candidate, CRLX101, is in clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated NDC clinical candidate, CRLX301, is in a Phase 1/2a clinical trial.

Oxford Instruments PLC (LSE:OXIG.L) is a provider of technology tools and systems for industry and research. The Company operates through three segments: Nanotechnology Tools, Industrial Products and Service. The Nanotechnology Tools segment offers technology products serving research customers in both the public and private sectors. The Industrial Products segment contains a group of businesses supplying technology products and components manufactured in medium volume for industrial customers. The Service segment contains the Company's service, rental and refurbished asset sales business. Its NanoAnalysis business delivers solutions and services that enable materials characterization and sample manipulation at the nano scale. Its products are used on electron microscopes and ion-beam systems in academic institutions and industrial applications, including semi-conductors, renewable energy, mining, metallurgy and forensics. Its products include AZtecOne and X-Max Extreme detector, among others.

PHI Group Inc. (OTC:PHIL) primarily focuses on acquisitions as a principal and invests in energy, natural resources and special situations that may substantially enhance shareholder value.  In addition, the Company also provides merger and acquisition advisory services through its wholly owned subsidiary PHI Capital Holdings, Inc. and earns revenues in forms of cash and equity for services rendered. Nanotech – January 2017: signed an agreement with Nhat Hai New Technology JSC, a Vietnam-based company specializing in applied research and nanotechnologies (http://www.nanotechnology.com.vn), to form a joint venture company in the United States to apply the latter’s nanotechnologies for the production of various nano products.

New Mining Companies Added:
Hadley Mining Inc. (CSE:HM) is a Toronto based mineral company which owns 25% of the Pigeon River nickel-copper claim in Ontario.

Secova Metals Corp (TSX:SEK.V; OTC:SEKZF; Frankfurt: N4UN.F) is a Canadian gold exploration company focused on building a strong asset base through exploration of undervalued gold projects in Canada. Management has demonstrated expertise in advancing gold exploration projects into acquisition targets, most notably in the province of Quebec. Secova has the exclusive right and option to acquire from Tres-Or Resources Inc. ("Tres-Or"), an undivided 65% right, title and interest in the contiguous Duvay and Chenier Gold Projects. Secova can earn up to 90% of the property (an additional 25% ownership) by funding a pre-feasibility study after the initial exploration expenditures to bring the property towards production. The Company has a total contiguous land package of 174 claims covering over 7,766 hectares (17,458 acres) of land. Duvay/Chenier is located in the Abitibi gold belt, one of Quebec's premier mining jurisdictions. The Company has plans to advance the development of Duvay/Chenier as well as seek other avenues of growth through acquisition and mergers. The Company also has 100% ownership of the Eagle River project which is adjacent to and on-trend to several gold projects in the Windfall Lake district of Urban Barry in Quebec. The Company wholly owns the Cobalt Bay property which is 1,996 hectares and just 102kms north of its Eagle River project in Quebec.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.  

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411